Catalent, Inc. (NYSE:CTLT) Shares Purchased by Arizona State Retirement System

Arizona State Retirement System boosted its stake in shares of Catalent, Inc. (NYSE:CTLT) by 0.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,546 shares of the company’s stock after acquiring an additional 365 shares during the quarter. Arizona State Retirement System’s holdings in Catalent were worth $2,226,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Tran Capital Management L.P. raised its stake in shares of Catalent by 12.2% during the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after purchasing an additional 39,208 shares during the last quarter. Raymond James & Associates increased its stake in Catalent by 23.2% in the 4th quarter. Raymond James & Associates now owns 149,279 shares of the company’s stock valued at $6,707,000 after buying an additional 28,106 shares during the period. SG Americas Securities LLC raised its position in Catalent by 240.0% during the 4th quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after buying an additional 28,410 shares during the last quarter. Westside Investment Management Inc. lifted its stake in shares of Catalent by 14.2% in the 4th quarter. Westside Investment Management Inc. now owns 21,273 shares of the company’s stock worth $956,000 after acquiring an additional 2,650 shares during the period. Finally, Dfpg Investments LLC boosted its holdings in shares of Catalent by 16.0% in the fourth quarter. Dfpg Investments LLC now owns 18,254 shares of the company’s stock valued at $777,000 after acquiring an additional 2,520 shares in the last quarter.

Catalent Trading Down 0.2 %

Shares of CTLT stock opened at $56.92 on Friday. The stock has a market cap of $10.29 billion, a P/E ratio of -8.37, a P/E/G ratio of 6.11 and a beta of 1.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $66.41. The business has a fifty day simple moving average of $56.95 and a 200-day simple moving average of $47.80.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent’s revenue was down 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.62 earnings per share. On average, analysts forecast that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CTLT has been the subject of several analyst reports. Barclays increased their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. UBS Group reissued a “neutral” rating and set a $63.50 target price (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. StockNews.com began coverage on Catalent in a research note on Thursday. They issued a “sell” rating on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. Finally, Stephens reissued an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Catalent has an average rating of “Hold” and an average target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.